After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Most recently, Yahoo Finance reported about the stock as it publicized that Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Avidity Biosciences Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $24.05 and fluctuated between $24.39 as its day high and $23.50 as its day low. The current market capitalization of Avidity Biosciences Inc is $1.92B. A total of 0.98 million shares were traded on the day, compared to an average of 1.19M shares.
In the most recent transaction, LEVIN ARTHUR A sold 5,000 shares of RNA for 23.97 per share on Mar 19 ’24. After the transaction, the Director now owns 14,830 company shares. In a previous transaction on Mar 13 ’24, MacLean Michael F sold 40,000 shares at 24.52 per share. RNA shares that Chief Financial Officer owns now total 44,093.
Among the insiders who sold shares, Boyce Sarah disposed of 28,000 shares on Mar 12 ’24 at a per-share price of $22.63. This resulted in the President and CEO holding 112,117 shares of RNA after the transaction. In another insider transaction, LEVIN ARTHUR A sold 27,641 shares at $22.03 per share on Mar 12 ’24. Company shares held by the Director now total 14,830.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, RNA has a high of $26.24 and a low of $4.82.
As of this writing, RNA has an earnings estimate of -$0.78 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.67 per share and a lower estimate of -$0.95. The company reported an EPS of -$0.71 in the last quarter, which was 7.80% higher than expectations of -$0.77.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. RNA’s latest balance sheet shows that the firm has $405.54M in Cash & Short Term Investments as of fiscal 2021. There were $11.73M in debt and $29.66M in liabilities at the time. Its Book Value Per Share was $6.32, while its Total Shareholder’s Equity was $381.43M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RNA is Buy with a score of 4.86.
